ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
Position in SPRO — Spero Therapeutics, Inc.
CIK 1164508
BOSTON, MA
Position in SPRO
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$735,863
+$452,893 QoQ
Shares Held
332,970
+121.2% QoQ
Ownership
0.572%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#11
of 59 holders
Holding Since
Jun 2020
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SPRO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ARROWSTREET CAPITAL, LIMITED PARTNERSHIP holds $2,515,799,583 across 71 Biotechnology names. SPRO ranks #60 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
738,378 | $366,774,503 | |
| 2 | INCY |
Incyte Corp
|
2,744,958 | $311,168,438 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
393,685 | $245,478,344 | |
| 4 | EXEL |
Exelixis, Inc.
|
4,365,926 | $237,550,033 | |
| 5 | GMAB |
Genmab A/S
|
4,975,324 | $136,672,150 | |
| 6 | RPRX |
Royalty Pharma plc
|
2,435,341 | $136,549,569 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
1,704,623 | $133,420,842 | |
| 8 | ONC |
BeOne Medicines Ltd.
|
249,758 | $71,173,537 |
All Filings in SPRO
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $735,863 | 332,970 | Shares | Defined | 2026-08-13 | |
| 2025-09-30 | $282,970 | 150,516 | Shares | Defined | 2025-11-13 | |
| 2020-09-30 | $381,951 | 34,225 | Shares | Defined | 2020-11-12 | |
| 2020-06-30 | $375,349 | 27,742 | Shares | Defined | 2020-08-12 | |
| No filing history on record for this holder in this stock. | ||||||